Strategic Expansion Eurofins CDMO is actively expanding its HPAPI development and manufacturing capabilities in Ontario and Mississauga, signaling opportunities to upsell integrated HPAPI services, kilolab capacity, and scalable GMP manufacturing for high-potency projects.

Integrated CMDO Scope The company offers end-to-end development from API/DS through DP, Formulation, analytical development, GMP manufacturing, packaging, and CMC regulatory affairs, presenting cross-selling opportunities across early development to clinical material supply for biologics and small molecules.

Regulatory Acclaim Accreditations with FDA, EMA, PMDA, Health Canada and other regulators position Eurofins CDMO as a trusted partner for clients seeking compliant, timely progression through development stages, enabling conversations around risk reduction and faster time-to-clinical milestones.

Cosmetics & Personal Care Synergy Recent SKIN CORE initiative and cosmetics-focused capabilities open doors to cross-sell from pharmaceutical CDMO services into cosmetics, personal care, and longevity claims, expanding potential client segments and co-development opportunities.

Strategic Acquisitions The acquisitions and lab expansions in packaging testing, material characterization, and food-contact materials indicate a broader capabilities moat; this creates potential for joint engagements with clients seeking integrated testing, contamination control, and supply-chain quality assurance across multiple verticals.